The global intravenous solutions market size was estimated to be USD 13.19 billion in 2023 and is expected to reach at USD 31.87 billion by 2034 with a CAGR of 8.35% during the forecast period 2024-2034. The rise in malnutrition cases, an increase in the elderly population, a growing incidence of illnesses such as cancer, neurological conditions, and gastrointestinal disorders, expanding research and development efforts, a surge in the introduction of new products, an increasing demand for advanced surgical treatments to enhance life expectancy, a growing need for intensive care and postoperative interventions, including parenteral nutrition products, a high prevalence of preterm births, improved healthcare infrastructure, an increase in healthcare spending and patient awareness, and an uptick in regulatory approvals for novel intravenous solutions are some of the key factors boosting the market growth.
An uptick in regulatory approvals for novel intravenous solutions is predicted to boost the market growth during the forecast period. Intravenous fluid regulation involves overseeing the quantity of fluids administered through an intravenous line directly into the bloodstream from a connected bag. The intravenous line, commonly referred to as an IV, is a slender tube inserted into one of the veins. The administration of fluids in this manner serves various purposes, including precise control of the volume delivered. In the absence of regulation, the rate of fluid delivery relies solely on gravity, leading to the potential for either overhydration or insufficient fluid intake. This therapy is employed for reasons such as rehydration following dehydration due to illness or strenuous activity. Consequently, market participants are actively developing innovative intravenous solutions, thereby fostering market growth. For instance, in June 2023, Vifor Pharma obtained FDA approval for Injectafer, the sole intravenous replacement therapy sanctioned for adult patients with heart failure and iron deficiency.
By product, total parenteral nutrition (TPN) was the highest revenue-grossing segment in the global intravenous solutions market in 2023 owing to the uptick in lifestyle-related diseases, a surge in the prevalence of chronic conditions, and an increasing introduction of novel products. For instance, in September 2022, B. Braun Inc. has introduced CARESAFE IV Administration Sets, which include an entirely voluntary AirStop component. Additionally, peripheral parenteral nutrition (PPN) is predicted to grow at fastest CAGR during the forecast period. The addition of PPN supplementation and adherence to Enhanced Recovery after Surgery (ERAS) programs have the potential to decrease postoperative complications. Additionally, patients who receive PPN show a reduced risk of complications compared to those undergoing conventional fluid therapy.
By nutrients, single-dose amino acid solution was the highest revenue-grossing segment in the global intravenous solutions market in 2023. Different studies have stated that single-dose amino acids provide a complete protein source, are customizable with other parenteral formulations, and can be easily administered. Additionally, vitamins & minerals is predicted to grow at fastest CAGR during the forecast period. Vitamins are vital for blood clotting, RBC formation, and maintaining mucus membranes. Deficiencies lead to anemia, beriberi, pellagra, and chronic mental conditions. Treatment involves parenteral or enteral nutrition. Minerals are essential organic chemicals that regulate metabolic pathways, including β-carotene, sodium chloride, magnesium, potassium, and phosphorous. Deficiency weakens the immune system & bones and causes fatigue due to poor mineral absorption. PN can be used for treatment in such cases. Therefore, market players are taking initiatives regarding the intravenous solutions which is anticipated to boost the market growth. For instance, in February 2023, Happy Head India, established in Hyderabad and Bengaluru, is the first IV wellness clinic in the country. The clinic provides IV drip sessions incorporating diverse infusions of vitamins and minerals to enhance overall health.
By bag type, small-volume bags (< 250 ml) was the highest revenue-grossing segment in the global intravenous solutions market in 2023 owing to the increase in the number of patients with diverse infectious diseases, a rising demand from blood bank centers, a heightened emphasis on the creation of PVC-free bags composed of non-latex materials by manufacturers of IV fluid bags for the secure and precise delivery of intravenous fluids, and a surge in regulatory endorsements. For instance, in June 2022, Breckenridge Pharmaceutical, Inc., a manufacturing company, announces that the U.S. Food and Drug Administration has granted approval for the Abbreviated New Drug Application concerning Cabazitaxel Intravenous Powder. Developed in collaboration with Natco Pharma Limited, a multinational pharmaceutical company, Breckenridge has received definitive approval for the 60mg/1.5mL (40mg/mL) strength. Additionally, large-volume bags (>250 ml) is predicted to grow at fastest CAGR during the forecast period owing to the increasing incidence of chronic diseases and a rising demand for large quantities of IV solutions.
By end-user, hospital & clinics was the highest revenue-grossing segment in the global intravenous solutions market in 2023 owing to the surge in the quantity of hospitals and clinics, an uptick in the prevalence of metabolic problems, and a rising patient population undergoing surgeries that require post-therapy intravenous solutions for various conditions and diseases in hospitals worldwide, accompanied by an increase in approvals from regulatory bodies. For instance, in January 2022, B. Braun Medical Inc. (B. Braun), a prominent figure in infusion therapy and pain management, disclosed that it has secured final approval from the U.S. Food & Drug Administration (FDA) for its recently established pharmaceutical manufacturing facility in Daytona Beach, FL. This facility is designated for the production of 0.9% Sodium Chloride for Injection, which will be accessible in B. Braun's Excel Plus IV Bags, offered in sizes of 1,000 mL and 500 mL. Additionally, home care is predicted to grow at fastest CAGR during the forecast period owing to the rise in the elderly population and the increasing preference among a substantial patient population for homecare settings.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing prevalence of diseases, a rise in the incidence of preterm births, a growing number of surgeries, robust reimbursement policies, and escalating investments by key market players. For instance, in August 2022, Assure Infusions, Inc. has disclosed a $20 million investment for the establishment of a cutting-edge manufacturing facility in Bartow, Florida, dedicated to the production of intravenous solutions. The company's objective is to address the demand-supply disparity for IV solutions in the United States. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the uptick in chronic diseases resulting from unhealthy dietary habits, a heightened demand for cost-effective treatment, expanding research and development efforts, a rising elderly population, and an increase in approvals from regulatory authorities. For instance, in March 2022, Otsuka Pharmaceutical Inc. obtained regulatory approval in Japan to market SAMTASU intravenous infusion for the treatment of cardiac edema.
An uptick in regulatory approvals for novel intravenous solutions is predicted to boost the market growth during the forecast period. Intravenous fluid regulation involves overseeing the quantity of fluids administered through an intravenous line directly into the bloodstream from a connected bag. The intravenous line, commonly referred to as an IV, is a slender tube inserted into one of the veins. The administration of fluids in this manner serves various purposes, including precise control of the volume delivered. In the absence of regulation, the rate of fluid delivery relies solely on gravity, leading to the potential for either overhydration or insufficient fluid intake. This therapy is employed for reasons such as rehydration following dehydration due to illness or strenuous activity. Consequently, market participants are actively developing innovative intravenous solutions, thereby fostering market growth. For instance, in June 2023, Vifor Pharma obtained FDA approval for Injectafer, the sole intravenous replacement therapy sanctioned for adult patients with heart failure and iron deficiency.
By product, total parenteral nutrition (TPN) was the highest revenue-grossing segment in the global intravenous solutions market in 2023 owing to the uptick in lifestyle-related diseases, a surge in the prevalence of chronic conditions, and an increasing introduction of novel products. For instance, in September 2022, B. Braun Inc. has introduced CARESAFE IV Administration Sets, which include an entirely voluntary AirStop component. Additionally, peripheral parenteral nutrition (PPN) is predicted to grow at fastest CAGR during the forecast period. The addition of PPN supplementation and adherence to Enhanced Recovery after Surgery (ERAS) programs have the potential to decrease postoperative complications. Additionally, patients who receive PPN show a reduced risk of complications compared to those undergoing conventional fluid therapy.
By nutrients, single-dose amino acid solution was the highest revenue-grossing segment in the global intravenous solutions market in 2023. Different studies have stated that single-dose amino acids provide a complete protein source, are customizable with other parenteral formulations, and can be easily administered. Additionally, vitamins & minerals is predicted to grow at fastest CAGR during the forecast period. Vitamins are vital for blood clotting, RBC formation, and maintaining mucus membranes. Deficiencies lead to anemia, beriberi, pellagra, and chronic mental conditions. Treatment involves parenteral or enteral nutrition. Minerals are essential organic chemicals that regulate metabolic pathways, including β-carotene, sodium chloride, magnesium, potassium, and phosphorous. Deficiency weakens the immune system & bones and causes fatigue due to poor mineral absorption. PN can be used for treatment in such cases. Therefore, market players are taking initiatives regarding the intravenous solutions which is anticipated to boost the market growth. For instance, in February 2023, Happy Head India, established in Hyderabad and Bengaluru, is the first IV wellness clinic in the country. The clinic provides IV drip sessions incorporating diverse infusions of vitamins and minerals to enhance overall health.
By bag type, small-volume bags (< 250 ml) was the highest revenue-grossing segment in the global intravenous solutions market in 2023 owing to the increase in the number of patients with diverse infectious diseases, a rising demand from blood bank centers, a heightened emphasis on the creation of PVC-free bags composed of non-latex materials by manufacturers of IV fluid bags for the secure and precise delivery of intravenous fluids, and a surge in regulatory endorsements. For instance, in June 2022, Breckenridge Pharmaceutical, Inc., a manufacturing company, announces that the U.S. Food and Drug Administration has granted approval for the Abbreviated New Drug Application concerning Cabazitaxel Intravenous Powder. Developed in collaboration with Natco Pharma Limited, a multinational pharmaceutical company, Breckenridge has received definitive approval for the 60mg/1.5mL (40mg/mL) strength. Additionally, large-volume bags (>250 ml) is predicted to grow at fastest CAGR during the forecast period owing to the increasing incidence of chronic diseases and a rising demand for large quantities of IV solutions.
By end-user, hospital & clinics was the highest revenue-grossing segment in the global intravenous solutions market in 2023 owing to the surge in the quantity of hospitals and clinics, an uptick in the prevalence of metabolic problems, and a rising patient population undergoing surgeries that require post-therapy intravenous solutions for various conditions and diseases in hospitals worldwide, accompanied by an increase in approvals from regulatory bodies. For instance, in January 2022, B. Braun Medical Inc. (B. Braun), a prominent figure in infusion therapy and pain management, disclosed that it has secured final approval from the U.S. Food & Drug Administration (FDA) for its recently established pharmaceutical manufacturing facility in Daytona Beach, FL. This facility is designated for the production of 0.9% Sodium Chloride for Injection, which will be accessible in B. Braun's Excel Plus IV Bags, offered in sizes of 1,000 mL and 500 mL. Additionally, home care is predicted to grow at fastest CAGR during the forecast period owing to the rise in the elderly population and the increasing preference among a substantial patient population for homecare settings.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing prevalence of diseases, a rise in the incidence of preterm births, a growing number of surgeries, robust reimbursement policies, and escalating investments by key market players. For instance, in August 2022, Assure Infusions, Inc. has disclosed a $20 million investment for the establishment of a cutting-edge manufacturing facility in Bartow, Florida, dedicated to the production of intravenous solutions. The company's objective is to address the demand-supply disparity for IV solutions in the United States. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the uptick in chronic diseases resulting from unhealthy dietary habits, a heightened demand for cost-effective treatment, expanding research and development efforts, a rising elderly population, and an increase in approvals from regulatory authorities. For instance, in March 2022, Otsuka Pharmaceutical Inc. obtained regulatory approval in Japan to market SAMTASU intravenous infusion for the treatment of cardiac edema.
Segmentation: Intravenous Solutions Market Report 2023 - 2034
Intravenous Solutions Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Peripheral Parenteral Nutrition (PPN)
- Total Parenteral Nutrition (TPN)
Intravenous Solutions Market Analysis & Forecast by Nutrients 2023 - 2034 (Revenue USD Bn)
- Vitamins & Minerals
- Parenteral Lipid Emulsion
- Carbohydrates
- Single-Dose Amino Acid Solutions
- Others
Intravenous Solutions Market Analysis & Forecast by Bag Type 2023 - 2034 (Revenue USD Bn)
- Large-Volume Bags (>250 ml)
- Small-Volume Bags (< 250 ml)
Intravenous Solutions Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Home Care
- Hospitals & Clinics
- Ambulatory Surgical Centers
Intravenous Solutions Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Intravenous Solutions Market: Product Estimates & Trend Analysis
8. Intravenous Solutions Market: Nutrients Estimates & Trend Analysis
9. Intravenous Solutions Market: Bag Type Estimates & Trend Analysis
10. Intravenous Solutions Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Intravenous Solutions Market
13. Europe Global Intravenous Solutions Market
14. Asia Pacific Global Intravenous Solutions Market
15. Latin America Global Intravenous Solutions Market
16. MEA Global Intravenous Solutions Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Otsuka Pharmaceutical Co. Ltd.
- Fresenius Kabi AG
- Breckenridge Pharmaceutical Inc.
- Assure Infusions Inc
- Pfizer Inc.
- B. Braun Medical Inc.
- JW Life Science
- Baxter
- Vifor Pharma Management Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 13.19 Billion |
| Forecasted Market Value ( USD | $ 31.87 Billion |
| Compound Annual Growth Rate | 8.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
